60 Degrees Pharmaceuticals expands ARAKODA access via Runway Health telehealth partnership

60 Degrees Pharmaceuticals (NASDAQ:SXTP) announced on April 15, 2026, a strategic partnership with Runway Health to make ARAKODA (tafenoquine) available to U.S. travelers via a dedicated telehealth platform.

This collaboration allows patients to consult with licensed clinicians through the Runway Health website, receive a clinical evaluation for malaria risk, and, if deemed appropriate, obtain a prescription for home delivery before their departure.

ARAKODA is an FDA-approved, broad-spectrum malaria preventive intended for adults aged 18 and older.

As a once-weekly alternative to traditional daily prophylaxis, the medication offers a streamlined regimen for those traveling to malaria-endemic regions.

Following an initial three-day loading phase prior to travel, the once-per-week maintenance dose is designed to improve patient compliance, which remains a significant hurdle in effective malaria prevention.

The integration into Runway Health’s digital storefront reflects a broader shift in travel medicine toward accessible, on-demand healthcare.